GlassScriptPhysician profile
Suresh G Kumar
NPI 1841496049
$11,502.33
in general payments reported to CMS, 2019-2025
68 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,238 · 2020: $841 · 2021: $2,069 · 2022: $1,554 · 2023: $1,463 · 2024: $1,935 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,714 · Education: $85.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,713.83 |
| Education | $85.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,718.87 | 2021-2025 | |
| Medtronic USA, INC. | $928.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $662.28 | 2021-2025 | Farxiga, Lokelma, Tezspire |
| Novo Nordisk INC | $606.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biogen, INC. | $472.60 | 2019-2025 | Vumerity, Tysabri |
| Amgen INC. | $436.49 | 2019-2025 | Tezspire, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.24 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $415.06 | 2019-2022 | |
| Argenx US, INC. | $358.61 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $345.43 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.37 | 2019-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $325.73 | 2019-2024 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $321.41 | 2020-2025 | Ajovy |
| Lilly USA, LLC | $295.58 | 2023-2025 | Jardiance, Zepbound, Emgality |
| E.R. Squibb & Sons, L.L.C. | $262.54 | 2019-2025 | Camzyos, Eliquis |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.